Company Profile

Avanti Biosciences Inc
Profile last edited on: 9/11/2020      CAGE: 5MR40      UEI: GZNJSM9ELXB3

Business Identifier: Small molecule compounds for treatment of Alzheimers and Hyperinsulinemia/Hyperammonemia Syndrome
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

25 Health Sciences Drive Mail Box 202
Stony Brook, NY 11790
Location: Single
Congr. District: 01
County: Suffolk

Public Profile

Avanti Biosciences, Inc. is a preclinical-stage biopharmaceutical company - and a current resident of JLabs San Diego - structured around development of new classes of drugs for treating CNS diseases including Alzheimer’s Disease and Down Syndrome and rare systemic diseases like Hyperinsulinemia Hyperammonemia syndrome (HHS or HI/HA) and cardiac amyloidosis. Management argue that current treatments for AD aim to maintain functional capability do not address underlying cause of the disease and thus have been unsuccessful in delaying disease progression. HHS is a rare genetic disease triggering severe recurrent hypoglycemia and elevated levels of ammonia that results in liver, kidney, and CNS complications, brain damage and death. Diazoxide has been used to treat hypoglycemia in HHS but may not treat neurological symptoms as it does not address the underlying cause of HHS.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Gian Luca Araldi -- Co-founder and CEO

  Sarah Araldi

Company News

There are no news available.